|
|
|
|
|
Sponsors and Collaborators: |
GlaxoSmithKline AGO Ovarian Cancer Study Group |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00561795 |
This is an open-label, two-arm, multicenter feasibility study to evaluate the safety and tolerability of pazopanib in combination with carboplatin and paclitaxel in female subjects with newly diagnosed advanced gynaecological tumors. Subjects will have received no prior therapy for their disease. A minimum of 12 and a maximum of 46 subjects will be enrolled. Dose schemas for each study arm are described in the protocol. For each arm, six subjects will be evaluated in treatment cohorts, which will be expanded to 20 subjects if initial toxicity is acceptable. Overall safety and tolerability of the regimen will be based on dose limiting toxicities, adverse events, and percentage of subjects that complete 6 courses of study treatment. Antitumor activity will be assessed using RECIST criteria and CA-125 responses.
Condition | Intervention | Phase |
Epithelial Ovarian Cancer Carcinoma Uterine Disease Tumor Primary Peritoneal Carcinoma Cervix Diseases |
Drug: Pazopanib (GW786034) |
Phase I Phase II |
MedlinePlus related topics: | Cancer Ovarian Cancer |
ChemIDplus related topics: | Carboplatin Paclitaxel Pazopanib |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase I/II, Open-Label, Multicenter, Two-Arm, Feasibility Study of Pazopanib, Carboplatin, and Paclitaxel in Women With Newly Diagnosed, Previously Untreated, Gynaecological Tumors |
Estimated Enrollment: | 46 |
Study Start Date: | October 2007 |
Estimated Study Completion Date: | November 2008 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion criteria:
A subject will be considered eligible for inclusion in this study only if all of the following criteria are met:
Subjects must provide written informed consent prior to performance of study specific procedures or assessments, and must be willing to comply with treatment and follow up.
•Procedures conducted as a part of routine clinical management of the subject (e.g., blood count, imaging study) and obtained prior to signed informed consent may be utilized for Screening or Baseline purposes provided these tests are obtained as specified in the protocol).
Female subjects ≥18 years of age with newly diagnosed advanced gynaecological malignancies for whom carboplatin and paclitaxel based chemotherapy is indicated. Patients may have surgery to debulk or resect disease but may not have received chemotherapy or radiotherapy.
Histological confirmation of the following: epithelial ovarian cancer, endometrial carcinoma, uterine sarcoma, mixed Müllerian tumour, fallopian tube carcinoma, primary peritoneal carcinoma, cervical carcinoma or vulvar carcinoma.
Performance status must be ECOG 0 1. Adequate organ system function as defined in Table 6 Table 6 Definitions for Adequate Organ Function
System (Laboratory Values)
Hematologic:
Absolute neutrophil count (ANC) (≥ 1.5 X 109/L) Hemoglobin1 (≥9 g/dL) Platelets (≥100 X 109/L) International normalized ratio (INR)(≤ 1.2 X upper limit of normal (ULN)) Partial thromboplastin time (PTT) (≤1.2 X ULN)
Hepatic:
Total bilirubin (≤1.5 X upper limit of normal (ULN)) AST and ALT (≤ 2.5 X ULN)
Renal:
Serum Creatinine (≤ 1.5 mg/dL) Or, if serum creatinine >1.5 mg/dL, (≥ 50 mL/min) Calculated creatinine clearance Urine Protein to Creatinine Ratio2 (<1)
Measurable or non-measurable disease.
A female subject is eligible to enter and participate in the study if she is:
•Of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any woman who: i. Has had a hysterectomy, or ii. Has had a bilateral oophorectomy (ovariectomy), or iii. Has had a bilateral tubal ligation, or iv. Is post-menopausal Subjects not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥ 1 year and be greater than 45 years in age, OR, in questionable cases, have a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value < 40pg/mL (<140 pmol/L).
Subjects who are using hormone replacement therapy and whose menopausal status is in doubt will be required to use a highly effective method of contraception (as outlined in this inclusion criterion) if they wish to continue their HRT during the study. Otherwise, these subjects must discontinue HRT prior to study enrollment to allow confirmation of post menopausal status. For most forms of HRT, at least 2-4 weeks must elapse between the cessation of HRT and determination of menopausal status; length of this interval depends on the type and dosage of HRT. Following confirmation of post menopausal status, these subjects can resume HRT during the study without use of contraception.
Childbearing potential, including any female who has had a negative serum pregnancy test within 2 weeks prior to the first dose of study treatment, preferably as close to the first dose as possible, and agrees to use adequate contraception. GSK acceptable contraceptive methods, when used consistently and in accordance with both the product label and the instructions of the physician, are as follow:
Note: Oral contraceptives are not reliable due to potential drug-drug interactions.
Female subjects who are lactating should discontinue nursing prior to the first dose of study drug and should refrain from nursing throughout the treatment period and for 14 days following the last dose of study drug.
1.1.2.Exclusion Criteria
A subject will not be eligible for inclusion in this study if any of the following criteria apply:
Clinically significant gastrointestinal abnormalities which might interfere with oral dosing, including but not limited to:
History of any one of more of the following cardiovascular conditions within the past 6 months:
Note: Subjects with recent DVT who have been treated with therapeutic anti-coagulant agents (excluding therapeutic warfarin) for at least 6 weeks are eligible.
Belgium | |||||
GSK Clinical Trials Call Centre | Recruiting | ||||
Leuven, Belgium, 3000 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 | |||||
Germany | |||||
GSK Clinical Trials Call Centre | Recruiting | ||||
Essen, Germany, 45122 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 | |||||
GSK Clinical Trials Call Centre | Not yet recruiting | ||||
Munchen, Germany, 80339 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 | |||||
GSK Clinical Trials Call Centre | Recruiting | ||||
Wiesbaden, Germany, 65199 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 | |||||
GSK Clinical Trials Call Centre | Recruiting | ||||
Dresden, Germany, 01307 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 | |||||
GSK Clinical Trials Call Centre | Recruiting | ||||
Marburg, Germany, 35043 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 | |||||
GSK Clinical Trials Call Centre | Recruiting | ||||
Kiel, Germany, 24105 | |||||
Contact: GSK Clinical Trials Call Center 1 877 379-3718 |
GlaxoSmithKline |
AGO Ovarian Cancer Study Group |
Study Chair: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | VEG110190 |
First Received: | November 19, 2007 |
Last Updated: | February 8, 2008 |
ClinicalTrials.gov Identifier: | NCT00561795 |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices; United States: Food and Drug Administration |
|
|
|
|